Bortolin Maria Teresa, Pratesi Chiara, Dolcetti Riccardo, Bidoli Ettore, Vaccher Emanuela, Zanussi Stefania, Tedeschi Rosamaria, De Paoli Paolo
Microbiology, Immunology and Virology Unit, Centro di Riferimento Oncologico, IRCCS, Via Pedemontana Occidentale, 12, Aviano (PN) 33081, Italy.
Cancer Lett. 2006 Feb 28;233(2):247-54. doi: 10.1016/j.canlet.2005.03.015.
We investigated EBV viremia in matched serum and peripheral blood mononuclear cells (PBMCs) from one of the largest Italian cohort of Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT) patients (N=34). By using a LMP-1 real-time PCR assay, we found that EBV DNA detection rate was 74% (median 8417 copies/ml) and 24% (median 164 copies/10(6)cells) on serum and PBMCs, respectively. Significantly higher serum EBV DNA levels were detected in patients with advanced UCNT (nodal stage N2 versus N0-1 and N3 versus N0-1, P=0.03 and 0.018; overall stage IV versus I-II, P=0.03). During the follow-up, there was also a statistically significant difference of EBV DNA viral load between patients with and without clinical relapse (P=0.008). We concluded that serum EBV DNA reflects the biological activity of the UCNT and may be a prognostic factor also in a low-incidence region.
我们对来自意大利最大的鼻咽癌未分化型癌（UCNT）患者队列之一（N = 34）的配对血清和外周血单个核细胞（PBMC）中的EBV病毒血症进行了研究。通过使用LMP-1实时PCR检测法，我们发现血清和PBMC中EBV DNA的检测率分别为74%（中位数8417拷贝/ml）和24%（中位数164拷贝/10⁶细胞）。在晚期UCNT患者中检测到显著更高的血清EBV DNA水平（淋巴结分期N2与N0 - 1以及N3与N0 - 1相比，P = 0.03和0.018；总体分期IV与I - II相比，P = 0.03）。在随访期间，有临床复发和无临床复发的患者之间EBV DNA病毒载量也存在统计学显著差异（P = 0.008）。我们得出结论，血清EBV DNA反映了UCNT的生物学活性，并且在低发病率地区也可能是一个预后因素。
